What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “CAL02 consists of a mixture of 2 liposomes and is a non-biological bacterial virulence neutralizer.”In the company’s words, NCT05776004 on ClinicalTrials.gov
- Tested for
- Pneumonia, Bacterial
- Main trialPhase 2
- “This is a placebo-controlled study to evaluate the addition of CAL02 to standard of care in treating hospitalized subjects diagnosed with severe community acquired bacterial pneumonia (SCABP) requiring critical care measures”In the company’s words, NCT05776004 on ClinicalTrials.gov
Other drugs for Pneumonia, Bacterial
- Pn-MAPS30plusGSK · Phase 1
- MP101MicrobiotiX Co., Ltd · Phase 1
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 10 Feb 2026 | Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026